结肠癌患者血浆miR-21表达水平与化疗药物疗效相关性的研究

Expression of miR-21 in plasma of patients with colon cancer and its relation to chemosensitivity

目的探讨结肠癌患者血浆中微小RNA-21(microRNA-21,miR-21)表达对化疗药物疗效的影响。方法对28例结肠癌晚期患者进行实时荧光定量聚合酶链反应法(real-time quantitative PCR,qRT-PCR)检测化疗前、后miR-21水平变化以及血浆中miR-21水平与FOLFOX4方案(奥沙利铂+亚叶酸钙+氟尿嘧啶)疗效的关系。结果经FOLFOX4方案化疗后血浆miR-21水平较化疗前降低(P=0.0392);化疗前血浆miR-21在(CR+PR)组的表达量低于(PD+SD)组,差异有统计学意义(P<0.05)。结论血浆中miR-21表达水平不同的结肠癌晚期患者其化疗药物的疗效也不相同,提示血浆miR-21有望成为预测化疗药物疗效的敏感性指标。

Objective To investigate the expression of microRNA-21（ miR-21） in the plasma of patients with colon carcinoma and its relation to chemosensitivity. Methods Twenty-eight patients with advanced colon carcinoma were treated with FOLFOX4 regimen（ oxaliplatin ＋ CF ＋ fluorouracil）. The expression of miR-21 in plasma was detected by realtime quantitative PCR（ qRT-PCR） before and after chemotherapy,and the association of miR-21 expression with chemotherapy efficacy was analyzed. Results Plasma miR-21 level was significantly decreased after chemotherapy（ P =0. 0392）. Plasma expression of miR-21 in（ CR ＋ PR） patients was significantly lower than that in（ PD ＋ SD） patients（ P 〈0. 05）. Conclusion The expression level of miR-21 in plasma may be associated with chemotherapy sensitivity of patients with advanced colon cancer.